Microbot Medical Inc. (NASDAQ:MBOT – Free Report) – Equities researchers at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for Microbot Medical in a report released on Wednesday, October 1st. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of ($0.06) per share for the quarter, up from their prior forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical’s Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.05) EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.10 EPS.
Get Microbot Medical alerts:
Microbot Medical (NASDAQ:MBOT – Get Free Report) last posted its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02).
Several other brokerages also recently commented on MBOT. Zacks Research downgraded Microbot Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a report on Saturday, September 27th. Finally, Wall Street Zen upgraded shares of Microbot Medical from a “sell” rating to a “hold” rating in a research report on Friday. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Microbot Medical has a consensus rating of “Hold” and an average price target of $12.00.
Check Out Our Latest Stock Analysis on MBOT
Microbot Medical Stock Performance
MBOT opened at $3.07 on Monday. The firm has a market cap of $162.07 million, a P/E ratio of -5.29 and a beta of 1.25. The business’s fifty day moving average is $3.33 and its 200-day moving average is $2.69. Microbot Medical has a 52-week low of $0.88 and a 52-week high of $4.67.
Hedge Funds Weigh In On Microbot Medical
Institutional investors have recently added to or reduced their stakes in the stock. U.S. Capital Wealth Advisors LLC bought a new stake in shares of Microbot Medical in the 2nd quarter worth approximately $25,000. American Century Companies Inc. purchased a new stake in Microbot Medical during the second quarter valued at about $32,000. Beacon Capital Management LLC lifted its stake in shares of Microbot Medical by 166.7% during the 2nd quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 10,000 shares in the last quarter. Virtu Financial LLC bought a new position in Microbot Medical in the 1st quarter worth approximately $42,000. Finally, XTX Topco Ltd purchased a new position in Microbot Medical in the 2nd quarter valued at approximately $43,000. Institutional investors own 16.30% of the company’s stock.
Microbot Medical Company Profile
(Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
See Also
Five stocks we like better than Microbot Medical
How to Calculate Options Profits
3 Defense Stocks Surging as Ukraine Tensions Deepen
Top Biotech Stocks: Exploring Innovation Opportunities
Starbucks Stock Slumps; This Competitor Shows Strength
What is a Death Cross in Stocks?
The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead
Q3 EPS Forecast for Microbot Medical Increased by Analyst
